CS
BLCM

Credit Suisse’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Credit Suisse’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,747
Closed -$93K – 4273
2019
Q1 		$93K Buy
2,747
+973
+55% +$32.5K ﹤0.01% 3854
2018
Q4 		$52K Buy
+1,774
New +$78.7K ﹤0.01% 3799
2018
Q3 		– Sell
-2,133
Closed -$158K – 4053
2018
Q2 		$158K Buy
2,133
+518
+32% +$40.4K ﹤0.01% 3792
2018
Q1 		$106K Buy
1,615
+240
+17% +$18.1K ﹤0.01% 3793
2017
Q4 		$116K Sell
1,375
-910
-40% -$89.2K ﹤0.01% 3822
2017
Q3 		$264K Buy
+2,285
New +$240K ﹤0.01% 3805
2017
Q2 		– Sell
-1,215
Closed -$150K – 3999
2017
Q1 		$150K Sell
1,215
-2,586
-68% -$339K ﹤0.01% 3656
2016
Q4 		$518K Buy
3,801
+1,085
+40% +$193K ﹤0.01% 3425
2016
Q3 		$540K Sell
2,716
-832
-23% -$143K ﹤0.01% 3374
2016
Q2 		$460K Buy
3,548
+428
+14% +$47.6K ﹤0.01% 3478
2016
Q1 		$291K Buy
3,120
+965
+45% +$105K ﹤0.01% 3524
2015
Q4 		$437K Buy
+2,155
New +$386K ﹤0.01% 3483

Other funds holding BLCM

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Credit Suisse's BLCM Position: Q2 2019 in Review

Credit Suisse sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2019, closing a stake of 2,747 shares — an estimated $93K sold.

Credit Suisse first reported a position in BLCM in Q4 2015 and held it in 12 quarters. The position peaked at $540K in Q3 2016. 79 funds tracked by Wall St. Rank hold BLCM as of Q2 2019.

  • Credit Suisse reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • Credit Suisse sold 2,747 Bellicum Pharmaceuticals, Inc. shares in Q2 2019, an estimated $93K.
  • Credit Suisse first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2015 and held it in 12 quarters.
  • Credit Suisse's Bellicum Pharmaceuticals, Inc. position peaked at $540K in Q3 2016.
  • 79 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2019.

Based on Credit Suisse's 13F filing for Q2 2019, filed 14 Aug 2019.